newsfilter
← Latest News
Business Wire·

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Multiple long-term follow-up studies confirm BRUKINSA's superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK degrader, BGB-16673,